Search

1 Dec 2012: Mark Turin. Dr Mark Turin, anthropologist, linguist and Director for the World Oral Literature Project, has spent more than 20 years travelling to and living in Nepal, much of that time

7 Feb 2012: 20 years of age, distinguished at a grammar-school, and going to Cambridge.”. ... After graduating with a good degree in mathematics in 1872, Henry was called to the Bar: after 20 years of successful advocacy in the Common Law Courts, Henry became

24 Jan 2012: To identify more precisely where the C-type gene variant originated, the researchers analysed DNA samples from more than 20 horse breeds, that included representatives of local British and Irish horses,

17 Aug 2012: Using these new materials could increase the harvesting ratio still further to 32:1 and extend the lifetime of a turbine installation from the present 20 years to up to 60 ... The wind turbine industry has experienced an average of 25 per cent per annum

14 Jan 2012: th. and early 20. th. century ideas. The series continues with an investigation into the origins of Gothic art and architecture in northern France in the twelfth century that features a ... 20 February: From Judgement to Atonement: Sculpture at Strasbourg

12 Nov 2012: His sacrifice was not enough. The remaining three companions struggled on a further 20 miles before making their final camp around 19 March, some 11 miles short of a depot that

31 May 2012: The guts of the book is a study of two heavyweights of 20.

13 Jan 2012: We hope that by gaining a better understanding of this relationship, we may then be able to understand why it is only within the last 20 years that spill-over to

1 Nov 2012: Additionally, alemtuzumab reduced the risk of acquiring disability by 42 per cent compared to interferon: disability worsened in 20% of interferon patients and 13% of alemtuzumab patients. ... During the trials, roughly 20 per cent of patients developed

10 Apr 2012: In approximately 20 per cent of cases studied, the tumours revealed groupings of genetic mutations (so-called 'actionable mutations') that already have potential clinical treatment options in the pipeline.